Patent intelligence · US
US 10772960
Stable aqueous formulations of adalimumab
Stable aqueous formulations of adalimumab
Patent details — US 10772960
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 15, 2020
- Expiration
- Sep 10, 2040
- Applicant
- Coherus BioSciences, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/542, A61K2039/545
Quick answer
US 10772960 (Stable aqueous formulations of adalimumab) is held by Coherus BioSciences, Inc.. Status: granted. Granted Sep 15, 2020. Expires Sep 10, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Coherus BioSciences, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/542, A61K2039/545, A61K39/39533, A61K39/3955
More from Coherus BioSciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11667702
Stable aqueous formulations of aflibercept
granted -
US 11583584
Stable protein compositions and methods of their use
granted -
US 11576971
Method of filling a container with no headspace
granted -
US 11426446
Stable aqueous formulations of aflibercept
granted -
US 11400072
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
granted -
US 11396540
Methods for making recombinant proteins
granted -
US 11253508
PPARy agonist for treatment of progressive supranuclear palsy
granted -
US 11229702
High concentration formulations of adalimumab
granted
Related coverage
Rise of Biosimilars in US: FDA Approval Trends & Market Impact
The article delves into the growing presence of biosimilars in the US market, focusing on FDA approval trends and their implications for drug pricing and patient access.
FDA Approves First Interchangeable Humira Biosimilar: Key Details
The FDA has approved the first interchangeable biosimilar to Humira, a significant milestone for patients with autoimmune conditions seeking affordable treatment alternatives.
Frequently asked questions
What is US patent 10772960?
US 10772960 (Stable aqueous formulations of adalimumab) is held by Coherus BioSciences, Inc.. Status: granted. Granted Sep 15, 2020. Expires Sep 10, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10772960?
Coherus BioSciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 73 pharmaceutical patents for this assignee.
When does US 10772960 expire?
Our index shows an expiration date of Sep 10, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.